Abstract：Objective: To investigate the value of chemokine receptor 4 (CCR4) in assessing postoperative recurrence and metastasis of colorectal cancer patients, and to establish a Cox survival risk score model. Methods: According to the expression of CCR4 detected by postoperative immunohistochemistry, the patients with colorectal cancer were divided into CCR4 positive group and CCR4 negative group. The general clinicopathological data of patients with CCR4 positive and CCR4 negative groups were compared. Taking postoperative tumor recurrence and metastasis as the dependent variable, multivariate Cox regression analysis was used to obtain the independent predictors of 5-year tumor recurrence and metastasis after operation, Kaplan Meier survival analysis compared the 5-year disease-free survival rate of patients between CCR4 positive group and CCR4 negative groups. Based on the independent predictors obtained by multivariate analysis, a Cox survival risk score model for predicting tumor recurrence and metastasis of colorectal cancer patients was established. Results: There were significant differences in the degree of differentiation, TNM / T stage and lymph node metastasis between the two groups (P<0.05). Multivariate Cox regression analysis showed that the degree of differentiation, TNM / T stage, lymph node metastasis and CCR4 were independent predictors of 5-year tumor recurrence and metastasis of patients after operation (P<0.05). Kaplan Meier survival analysis showed that 1-year,3-year and 5 year disease-free survival rates of the patients in CCR4 negative group were significantly higher than those of patients in CCR4 positive group (72.3%, 54.2%, 38.6% vs 54.5%, 31.9%, 24.5%, P<0.05). A Cox survival risk score model for predicting the 5-year risk of tumor recurrence and metastasis of patients with colorectal cancer was constructed based on the 4 independent predictors of differentiation, TNM / T stage, lymph node metastasis and CCR4. The best cutoff value of the risk score was -0.08, the patients were divided into high-risk group and low-risk group with the cutoff value. The Cox survival risk score model showed that the higher the Cox survival risk score, the higher the risk of postoperative tumor recurrence and metastasis of patients. Conclusion: The Cox survival risk score model combined with CCR4 can be used to predict the risk of 5-year tumor recurrence and metastasis of colorectal cancer patients after operation.
伍远浩, 黄平, 李来春. 趋化因子受体4对结直肠癌患者术后复发转移的评估价值[J]. 河北医学, 2022, 28(8): 1361-1365.
WU Yuanhao, HUANG Ping, LI Laichun. Value of Chemokine Receptor 4 in the Assessment of Postoperative Recurrent Metastasis in Patients with Colorectal Cancer. HeBei Med, 2022, 28(8): 1361-1365.
[1] Hashiguchi Y,Muro K,Saito Y,et al.Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer[J].Int Clin Oncol,2020,25(1):1-42. [2] Lu Y,Kweon SS,Cai Q,et al.Identification of novel loci and new risk variant in known loci for colorectal cancer risk in east asians[J].Cancer Epidemiol Biomarkers Prev,2020,29(2):477-486. [3] Murphy N,Carreras-Torres R,Song M,et al.Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and mendelian randomization analyses[J].Gastroenterology,2020,158(5):1300-1312. [4] 王保国,陈子辉,梁春芳.趋化因子受体CCR4在结直肠癌组织中表达及临床意义[J].临床军医杂志,2019,47(1):81-82. [5] Ou B,Zhao J,Guan S,et al.CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer published correction appears in Oncotarget[J].Oncotarget,2016,7(30):47637-47649. [6] 吕杨波,邱丹,陈震宏.趋化因子受体表达与结直肠癌淋巴结转移的关系研究[J].浙江医学,2021,23(12):1295-1303. [7] Chalabi Hagkarim N,Grand RJ.The regulatory properties of the Ccr4-not complex[J].Cells,2020,9(11):2379. [8] Zaravinos A,Roufas C,Nagara M,et al.Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer[J].Exp Clin Cancer Res,2019,38(1):364. [9] Zhang Y,Chen K,Li L,et al.CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma[J].Ann Transl Med,2021,9(18):1443. [10] Marshall LA,Marubayashi S,Jorapur A,et al.Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4[J].Immunother Cancer,2020,8(2):e000764.
2022, Vol. 28 
冀公网安备13080202000677号